tirzepatide
Manufactured by Eli Lilly
Available Brands
Mounjaro
FDA-approved for type 2 diabetes only. Weekly injection, same active ingredient as Zepbound.
See Mounjaro savings and coverage →Zepbound
FDA-approved for chronic weight management and obstructive sleep apnea. Weekly injection.
See Zepbound savings and coverage →Overview
FDA Status
FDA Approved
Route
injection
Approved Indications
Dosing
Typical Dose Range
2.5mg - 15mg weekly
Dosing is determined by your prescribing provider based on your individual needs. Most GLP-1 medications follow a gradual titration schedule, starting at a low dose and increasing over several weeks to reduce side effects.
Cost Breakdown
Branded (Retail)
$1,100/mo
Savings Program
$299/mo
Prices are estimates and may vary by pharmacy, location, and insurance coverage. Contact your provider for accurate pricing.
Common Side Effects
- nausea
- vomiting
- diarrhea
- decreased appetite
- constipation
This is not a complete list of side effects. Talk to your healthcare provider about what to expect and when to seek medical attention.
This site is for educational purposes only and is not medical advice. Always consult a healthcare provider before starting any medication. Full disclaimer
Complete Zepbound guide for 2026
Zepbound is tirzepatide prescribed for weight loss. See our full pillar covering every coupon, cost breakdown, and access path.
Related Articles
Zepbound and Pregnancy: The 2-Month Washout Rule (2026 Guide)
Why Lilly's label says to stop Zepbound 2 months before conception, the oral contraceptive interaction window most patients don't hear about, and exactly what to do if you find out you're pregnant on tirzepatide.
GLP-1 Supplements: The Truth About 'Natural Ozempic' in 2026
Berberine, ACV gummies, fiber blends, 'GLP-1 boosting' probiotics. What the science actually says about these so-called natural Ozempic alternatives, what they cost, and when (if ever) they make sense.
GLP-1 Microdosing: A 2026 Guide to Lower-Dose Semaglutide and Tirzepatide
What GLP-1 microdosing actually is, why patients are using semaglutide and tirzepatide at 25-50% of the standard dose, what the limited data shows, and how to do it safely with a prescriber.
What Happens When You Stop GLP-1s — and What the Maintenance-Dose Data Actually Shows
The standard line is that you regain the weight. The actual picture is more nuanced. Here's what trials show happens when patients come off Wegovy or Zepbound, and why a low maintenance dose is becoming the recommended approach.